Calls to End Industry’s ‘Financial Entanglement’ With Healthcare Players
Financial ties between companies and healthcare bodies distort the production and use of evidence, claims a paper co-authored by researchers, clinicians and decision makers, including a representative of Germany’s HTA body, IQWiG.
You may also be interested in...
The European Medicines Agency has rejected claims that industry fees and allegedly flawed methods of evaluating medicines can lead to problematic development and interpretation of evidence.
Meindert Boysen, head of NICE’s Centre For Health Technology Evaluation, shares advice for companies aiming to get their medicine to patients. His golden rules: engage in early advice and be more realistic about pricing.
In an exclusive interview with the Pink Sheet, senior NICE director Meindert Boysen reveals the best advice he ever received and how companies whose products are under review can improve their chances of success.